NCT06381180 Warrior CARE: Cannabis Behavioral Health
| NCT ID | NCT06381180 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Wayne State University |
| Condition | Post Traumatic Stress Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-09-22 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 500 participants in total. It began in 2025-09-22 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a randomized, controlled clinical trial to examine the therapeutic potential of cannabinoids for treating veterans with PTSD and suicidal ideation.
Eligibility Criteria
Inclusion Criteria: * a healthy veteran who has served in a branch of the US armed forces * report using cannabis within the past year * currently meet DSM-5 criteria for PTSD and a score of 25 or greater on the CAPS-5 (the anchor, or index, trauma does not have to be related to military service) * between the ages of 19-69 years old * not seeking treatment for Cannabis Use Disorder * stable (i.e., under the care of a physician or therapist and not experiencing acute symptoms) on psychotropic medications and/or psychotherapy before the study begins (participants can be in treatment for PTSD) * agree to adhere to study procedures Exclusion Criteria: * pregnant, lactating, or heterosexually active women and not using medically approved birth control * current or past bipolar or psychotic disorder as determined using the SCID-5 * at immediate high risk for suicide based on the C-SSRS * current SUD other than Nicotine Use Disorder and Alcohol Use Disorder (mild or moderate) * allergies and/or other contradictions for using cannabis * any clinically significant medical problems * systolic/diastolic BP \>140/90 mmHg or systolic BP \<95 mmHg * elevated liver function tests * exhibit cognitive impairment (\<80 IQ) * enrolled in another clinical trial or have received any drug as part of a research study within 30 days of dosing * used a prescription medication (with the exception of birth control) within 14 days of study entry that in the opinion of the medically responsible investigator will interfere with the safety of the participant or the study results * unable to provide informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06381180 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 69 Years, studying Post Traumatic Stress Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06381180 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06381180 currently recruiting?
Yes, NCT06381180 is actively recruiting participants. Contact the research team at llundahl@wayne.med.edu for enrollment information.
Where is the NCT06381180 trial being conducted?
This trial is being conducted at Detroit, United States.
Who is sponsoring the NCT06381180 clinical trial?
NCT06381180 is sponsored by Wayne State University. The trial plans to enroll 500 participants.